1133-P: Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge Type 2 Diabetes Patients—An Exploratory Study

Post-hospital discharge (PHD) can be a challenging time for health care providers (HCPs) and patients. We analyzed use of Dexcom G6 CGMs in PHD T2D patient management. This study analyzed 30 days of PHD remote monitoring data for 28 T2D patients. Hospital discharge summaries and telehealth notes were analyzed for details around hospital stay, PHD outcomes, and patient-HCP interactions. Study sample was categorized into 3 cohorts to reflect disease severity and risk of mortality during hospitalization- Group A (Organ Transplants), Group B (High Severity), Group C (Medium Severity) (Table). Overall, Group B was the youngest (median (IQR): 37 years (37,55)) vs. Groups A Dexcom, Inc. C. Hicks: Employee; Dexcom, Inc. T. Zhou: None. Y. Xu: Employee; Dexcom, Inc. H. Singh: Employee; Dexcom, Inc. D.R. Cherñavvsky: None. C. Levister: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc. N. Shah: None. M. Rouviere: None. A. Tamru: None. L. Kaplan: None. D.W. Lam: Research Support; Renalytix. G. O'Malley: Research Support; Dexcom, Inc., Insulet Corporation, Abbott, Tandem Diabetes Care, Inc., MannKind Corporation. C.J. Levy: Research Support; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, T1D Exchange, Tandem Diabetes Care, Inc., Abbott, Insulet Corporation.